GlassScriptPhysician profile
Harshivinderjit Singh Bains
NPI 1720199599
$5,559.43
in general payments reported to CMS, 2019-2025
19 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $69.15 · 2021: $175 · 2022: $131 · 2023: $592 · 2024: $3,067 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183 · Travel and Lodging: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.26 |
| Travel and Lodging | $1,873.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $2,468.30 | 2022-2024 | |
| Genentech USA, INC. | $798.80 | 2019-2025 | Susvimo, Vabysmo |
| Regeneron Healthcare Solutions, INC. | $461.97 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $420.70 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $315.47 | 2023-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $182.45 | 2025 | Eylea Hd |
| Astellas Pharma US INC | $164.28 | 2023-2025 | Izervay |
| Allergan, INC. | $148.53 | 2019-2021 | |
| Abbvie INC. | $140.74 | 2022-2025 | Ozurdex |
| Horizon Therapeutics Plc | $121.89 | 2021-2023 | Tepezza |
| Genentech, INC. | $82.26 | 2023 | Vabysmo |
| Harrow Eye, LLC | $63.01 | 2025 | Iheezo |
| Ani Pharmaceuticals, INC. | $46.14 | 2025 | Yutiq, Iluvien |
| Amgen INC. | $35.33 | 2024 | Tepezza |
| Bausch & Lomb Americas INC. | $32.82 | 2023 | Vyzulta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.83 | 2019-2020 | |
| Sandoz INC. | $20.11 | 2024 | Cimerli |
| Dutch Ophthalmic, USA | $16.00 | 2025 | Eva, Combined Machine, Tissueblue |
| Aerie Pharmaceuticals, INC. | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshivinderjit Bains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.